Metal-Protein Attenuating Compounds (MPACs) for the Treatment of Alzheimer's Disease

ISSN： 1567-2697

Source： Drug Design Reviews - Online, Vol.1, Iss.1, 2004-01, pp. : 75-82

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Metal-protein attenuating compounds and Alzheimer’s disease

By Ritchie Craig W Bush Ashley I Masters Colin L

Expert Opinion on Investigational Drugs, Vol. 13, Iss. 12, 2004-12 ,pp. : 1585-1592

Informa Healthcare

Access to resources Recommend Favorite

Metal-Protein Attenuating Compounds (MPACs): An Emerging Approach for the Treatment of Neurodegenerative Disorders

Current Bioactive Compounds, Vol. 4, Iss. 2, 2008-08 ,pp. : 57-67

Bentham Science Publishers

Access to resources Recommend Favorite

The Potential Effect of Fluorinated Compounds in the Treatment of Alzheimer’s Disease

Current Pharmaceutical Design, Vol. 21, Iss. 39, 2015-12 ,pp. : 5725-5735

Bentham Science Publishers

Access to resources Recommend Favorite

Natural Products as Sources of New Lead Compounds for the Treatment of Alzheimer’s Disease

Current Topics in Medicinal Chemistry, Vol. 13, Iss. 15, 2013-08 ,pp. : 1864-1878

Bentham Science Publishers

Access to resources Recommend Favorite

Treatment strategies in Alzheimer's disease

By Levy R.

European Neuropsychopharmacology, Vol. 5, Iss. 3, 1995-09 ,pp. : 204-205

Elsevier

Access to resources Recommend Favorite